



## BIOEUROPE PRESENTATION – SEEKING OPPORTUNITIES IN ONCOLOGY

F. R. Martelet, M.D., CEO

*26 – 29 October 2020*

# Forward-looking statement

## **IMPORTANT NOTICE**

*The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.*

*No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.*

*The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.*

## **FORWARD LOOKING STATEMENTS**

*This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.*

*Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.*

*This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.*


# Oasmia – an innovation-focused specialty pharmaceutical company




Founded in **1999**  
Based in Uppsala, Sweden



**XR-17™ technology platform**  
Enhances the intravenous delivery of established and novel drugs in diseases including cancer



A growing pipeline, focused on **Oncology** and with potential in other therapeutic areas



NASDAQ Stockholm **2010**  
Market Cap approx. SEK 2.0 B



**R&D-focused Production**  
Facility in Uppsala, Sweden



**New Leadership**  
since March 2020

# The new team leading Oasmia's transformation



**FRANCOIS MARTELET, M.D., Master's Degree Business**  
*Chief Executive Officer*

**Previous experience:**  
CEO in Biotechnology/ BioPharma in UK, Denmark, US and senior executive global roles at Novartis Oncology, Merck & Co., Inc with large P&L responsibility



**ANDERS HÄRFSTRAND, M.D., PhD.**  
*Non-executive Chairman*

**Previous experience:** Pharma BoD, M&A, former executive positions in Pfizer, Pharmacia, Pharmacia & Upjohn

**FREDRIK JÄRRSTEN\***  
*Chief Finance Officer*

**ELIN TRAMPE,**  
*Chief Technical Officer*

**REINHARD KOENIG, M.D.**  
*Acting Chief Medical Officer*

**PETER SELIN\***  
*Chief Business Officer*

**HEGE HELLSTRÖM,**  
**B.A.**  
*Board Member*

**BIRGIT STATTIN NORINDER, MSc.**  
*Board Member*

**PETER ZONABEND,**  
**LL.M, EMLE**  
*Board Member*



# Meeting the challenges of poor drug solubility

## POOR API<sup>1</sup> SOLUBILITY

Major challenge in  
drug development

Critical to drug  
bioavailability

## c.40% OF APPROVED DRUGS AFFECTED<sup>2</sup>

70-90% of pipeline  
drugs classed as  
poorly soluble<sup>2</sup>

Leading cause of  
project  
termination

## A FACTOR IN SERIOUS ADVERSE EVENTS (SAEs)

Solubility enhancers  
can cause SAEs and/  
or require use of  
further drugs

An accepted trade  
off in cancer  
therapy

\$180 bn  
SPENT ON  
PHARMA R&D  
EVERY YEAR<sup>3</sup>


69%  
OF DRUGS  
FAIL DUE TO  
LOW  
SOLUBILITY<sup>3</sup>

1) API = Active Pharmaceutical Ingredient - the ingredient in a pharmaceutical drug that is biologically active  
2) Nikolakakis & Partheniadis  
3) GlobalData



# XR-17™ powerful platform that can increase solubility of insoluble compounds

Active Pharmaceutical Ingredient  
(API)



**WATER INSOLUBLE**




**XR-17™**



Hydrophilic head  
Hydrophobic chain



XR-17™ + API




**WATER SOLUBLE**

**XR-17™ increases small molecule solubility and potentially improves safety and efficacy of new formulations**



# XR-17™ – the solution to your water solubility issues





## XR-17™ – platform validated by success of Apealea® in oncology



Drug load capacity, enabling high drug delivery capability



Shorter infusion time<sup>1,2</sup>



Superior solubility compared with other platforms and technologies, enhances bioavailability of API



Strong, validated safety in cancer indication<sup>1</sup>




No mandatory or limited need for steroid pre-medication<sup>1</sup>




Free from alcohol, Cremophor EL, Polysorbate-80 and Human albumin, which can cause numerous side effects



# Building a diverse portfolio based on XR-17™ platform technology



| Product                                  | Indication                        | Pre-clinical | Phase I  | Phase II | Phase III | Registration / approval | Geography |        |
|--|-----------------------------------|--------------|--|----------|-----------|-------------------------|-----------|--------|
| <b>Human Health Portfolio</b>            |                                   |              |  |          |           |                         |           |        |
| Apealea® /<br>Paclical®<br>(paclitaxel)  | Ovarian cancer                    | ▶            |  |          |           | Pre-NDA meeting         | USA       |        |
|  | Ovarian cancer                    | ▶ ✓          |  |          |           |                         | EU / EEA  |        |
| Docetaxel<br>micellar                    | Prostate cancer                   | ▶            |  |          |           |                         | Global    |        |
| New API                                  | Undisclosed                       | ▶            |  |          |           |                         |           | Global |
| XR-19<br>(combination)                   | Assessments in<br>various cancers | ▶            |  |          |           |                         |           | Global |
| <b>Animal Health Portfolio (Canines)</b> |                                   |              |  |          |           |                         |           |        |
| Paccal vet<br>(paclitaxel)               | Mammary<br>Carcinoma              | ▶            |  |          |           |                         |           | USA    |
| Doxophos vet<br>(doxorubicin)            | Lymphoma                          | ▶            |  |          |           |                         |           | USA    |





# Apealea® – offering an improved treatment option



**Approved in EU/EEA for treatment of first relapse ovarian cancer<sup>1</sup> and in Russia for first line and relapsed ovarian cancer<sup>2</sup>**

Current standard of care in Ovarian cancer is carboplatin + paclitaxel

A subset of patients cannot tolerate solvent-based paclitaxel

Apealea® is a solvent-free IV formulation of paclitaxel using XR-17™

- *Free from polyoxyethylated castor oil and dehydrated alcohol*
- *No need for mandatory glucocorticosteroids pre-medication*
- *Shorter infusion and overall 'chair' time*



1) Apealea® Summary of Product Characteristics. [www.ema.europa.eu](http://www.ema.europa.eu)

2) Paclical® Instructions for medical use. <https://grls.rosminzdrav.ru>



# Apealea<sup>®</sup> – global partnership worth up to \$698m + royalties



Agreement with US-based Elevar Therapeutics, subsidiary of South Korea's HLB



\$20<sub>M</sub>

Upfront payment

%

Double digit royalties on global Apealea<sup>®</sup> sales

\$678M


Milestones based on regulatory and sales achievements




Oasmia retains sole control over development of XR-17<sup>™</sup> in other APIs



Named patient program initiated with Tanner Pharma Group ex US  
Elevar recently announced a commercialization agreement with Taiba for MENA markets;  
negotiations with partners for other key markets advancing well



# Oasmia's business model



Model successfully applied to Apealea<sup>®</sup>, out-licensed globally to Elevar Therapeutics



## In-licensing opportunities mainly in oncology



- Oasmia is also open to collaborations to support partners' R&D and overcome solubility challenges

Arrange a meeting with us via the BioEurope partnering system to find out more.....



# Out-licensing opportunities in animal health portfolio

## Paccal Vet

- A new XR-17™-based formulation of paclitaxel in development for the treatment of mastocytoma in dogs
  - Identical to Apealea® / Paclical (for human use)
- Preparations for a new study are ongoing, with the outcome serving as the basis for registration strategies in Europe and the US

## Doxophos Vet

- A patented formulation of doxorubicin in combination with XR-17™
- In development for the treatment of lymphoma, one of the most common forms of cancer in dogs
- Results from Phase I and Phase II studies will form part of the application to the FDA for conditional approval

Arrange a meeting with us via in the BioEurope partnering system to find out more.....

# Building a sustainable, profitable specialty pharma company



## APEALEA® APPROVED IN EUROPE



Lead product  
launched for  
advanced ovarian  
cancer

Opportunity to  
develop in several  
other cancer  
indications

## A GLOBAL PARTNERSHIP



Elevar Apealea® deal  
worth up to \$678  
million plus royalties

Elevar evaluating  
European and Asian  
commercial partners

## A GROWING ONCOLOGY PIPELINE



Underpinned by  
strong IP protection

Docetaxel micellar  
poised for the clinic

XR-19 and a new API  
in preclinical  
development

## WELL POSITIONED FOR PARTNERING / M&A



Proven development,  
regulatory and BD  
skills

Lean flexible  
structure with low  
cash burn and solid  
cash position

## Contact us for more information



Find out more about our partnering opportunities by emailing our partnering team at:

[partners@oasmia.com](mailto:partners@oasmia.com)